Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo A Bartholomew, C Sturgeon, M Siatskas, K Ferrer, K McIntosh, S Patil, ... Experimental hematology 30 (1), 42-48, 2002 | 3303 | 2002 |
Lenalidomide after stem-cell transplantation for multiple myeloma PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ... New England Journal of Medicine 366 (19), 1770-1781, 2012 | 1328 | 2012 |
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients HM Lazarus, ON Koc, SM Devine, P Curtin, RT Maziarz, HK Holland, ... Biology of blood and marrow transplantation 11 (5), 389-398, 2005 | 1187 | 2005 |
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates SM Devine, C Cobbs, M Jennings, A Bartholomew, R Hoffman Blood, The Journal of the American Society of Hematology 101 (8), 2999-3001, 2003 | 1038 | 2003 |
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody DM Benson Jr, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, ... Blood, The Journal of the American Society of Hematology 116 (13), 2286-2294, 2010 | 945 | 2010 |
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling … V Ratanatharathorn, RA Nash, D Przepiorka, SM Devine, JL Klein, ... Blood, The Journal of the American Society of Hematology 92 (7), 2303-2314, 1998 | 706 | 1998 |
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia SO Ciurea, MJ Zhang, AA Bacigalupo, A Bashey, FR Appelbaum, ... Blood, The Journal of the American Society of Hematology 126 (8), 1033-1040, 2015 | 665 | 2015 |
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion SM Devine, AM Bartholomew, N Mahmud, M Nelson, S Patil, W Hardy, ... Experimental hematology 29 (2), 244-255, 2001 | 638 | 2001 |
International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, ... Biology of Blood and Marrow Transplantation 22 (1), 4-10, 2016 | 631 | 2016 |
Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes BL Scott, MC Pasquini, BR Logan, J Wu, SM Devine, DL Porter, ... Journal of Clinical Oncology 35 (11), 1154, 2017 | 605 | 2017 |
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine W Blum, R Garzon, RB Klisovic, S Schwind, A Walker, S Geyer, S Liu, ... Proceedings of the National Academy of Sciences 107 (16), 7473-7478, 2010 | 589 | 2010 |
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated … CG Brunstein, EJ Fuchs, SL Carter, C Karanes, LJ Costa, J Wu, ... Blood, The Journal of the American Society of Hematology 118 (2), 282-288, 2011 | 577 | 2011 |
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone N Flomenberg, SM Devine, JF DiPersio, JL Liesveld, JM McCarty, ... Blood 106 (5), 1867-1874, 2005 | 561 | 2005 |
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results … P Armand, A Nagler, EA Weller, SM Devine, DE Avigan, YB Chen, ... Journal of clinical oncology 31 (33), 4199, 2013 | 554 | 2013 |
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma SM Devine, N Flomenberg, DH Vesole, J Liesveld, D Weisdorf, K Badel, ... Journal of Clinical Oncology 22 (6), 1095-1102, 2004 | 531 | 2004 |
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma J Chu, Y Deng, DM Benson, S He, T Hughes, J Zhang, Y Peng, H Mao, ... Leukemia 28 (4), 917-927, 2014 | 467 | 2014 |
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations S Giralt, L Costa, J Schriber, J DiPersio, R Maziarz, J McCarty, ... Biology of Blood and Marrow Transplantation 20 (3), 295-308, 2014 | 435 | 2014 |
Current use of and trends in hematopoietic cell transplantation in the United States A D'Souza, C Fretham, SJ Lee, M Arora, J Brunner, S Chhabra, S Devine, ... Biology of Blood and Marrow Transplantation 26 (8), e177-e182, 2020 | 416 | 2020 |
Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies RJ Soiffer, J LeRademacher, V Ho, F Kan, A Artz, RE Champlin, S Devine, ... Blood, The Journal of the American Society of Hematology 117 (25), 6963-6970, 2011 | 395 | 2011 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia W Blum, RB Klisovic, B Hackanson, Z Liu, S Liu, H Devine, ... Journal of Clinical Oncology 25 (25), 3884-3891, 2007 | 380 | 2007 |